KCT0008416尚未招募Unknown
Reduce neutropenia by changing the date of eflapegrastim administration in breast cancer patients who have experienced neutropenia after chemotherapy
Eunseong Medical Foundation Good Gang-an Hospital0 个研究点目标入组 100 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18(Year) 至 75(Year)（—）
- 性别
- Female
入选标准
- •Women aged 18 to 75 years old as of the date of study registration.
- •Patients with histologically confirmed invasive adenocarcinoma.
- •Patients with confirmed estrogen receptor, progesterone receptor, and Her2 receptor status.
- •Patients with ECOG performance status 0-1.
- •Patients with a left ventricular ejection fraction (LVEF) =55%.
- •Patients who have agreed to participate in this trial and have provided written consent.
排除标准
- •Patients with a history of breast cancer treatment
- •Patients with a history of chemotherapy, radiation therapy, immunotherapy, or biotherapy for malignancies other than breast cancer
- •Patients with infectious diseases
- •Patients with serious illnesses that may affect this clinical trial: cardiovascular disease, kidney disease, liver disease, endocrine disease, tumors, or diabetes
- •Other individuals deemed by the clinical trial investigators to be unable to participate in the trial.
研究者
相似试验
招募中
4 期
Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After ChemotherapyBreast NeoplasmsNCT05949333Eunseong Medical Foundation Good GANG-AN HOSPITAL100
进行中（未招募）
1 期
Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-CancerNeutropeniaBreast CancerNCT04187898Spectrum Pharmaceuticals, Inc50
已完成
3 期
Prophylaxis of febrile neutropenia by reducing chemotherapy-induced gastrointestinal mucosal injuryfebrile neutropeniaJPRN-UMIN000011065Juntendo University School of Medicine75
已完成
3 期
EVOFLOXACIN PREVENTS FEBRILE NEUTROPENIA DURING CYTARABINE CONSOLIDATION (IDAC/HIDAC) IN ACUTE MYELOID LEUKEMIAWe aimed to evaluate the efficacy of levofloxacin for febrile neutropenia prevention following cytarabine containing consolidation chemotherapy (intermediate dose-IDAC or high dose-HIDAC) in newly diagnosed AML patients.AML , febrile neutropenia, levofloxacinTCTR20240401009none36
已完成
3 期
Validation study of new febrile neutropenia guideline-Comparative study between oral levofloxacin and parenteral cefepime in low-risk patients with febrile neutropeniaFebrile neutropeniaJPRN-C000000396Japan Febrile Neutropenia Study Group200